Subscribe: pubmed: "Lautenschlager I"[A...
http://eutils.ncbi.nlm.nih.gov/entrez/eutils/erss.cgi?rss_guid=0eWb8uS_BpLJSrTVZZo0-2Bv32UqqGsCR9At91E6lrT
Preview: pubmed: "Lautenschlager I"[A...

pubmed: "Lautenschlager I"[A...



NCBI: db=pubmed; Term="Lautenschlager I"[Author]



 



HHV-6 in Liver Transplantation: A Literature Review.
Related Articles

HHV-6 in Liver Transplantation: A Literature Review.

Liver Int. 2017 Jun 26;:

Authors: Phan TL, Lautenschlager I, Razonable RR, Munoz FM

Abstract
Human herpesvirus 6 (HHV-6A and HHV-6B) can cause primary infection or reactivate from latency in liver transplant recipients, which can result in a variety of clinical syndromes, including fever, hepatitis, encephalitis, and higher rates of graft dysfunction as well as indirect effects including increased risks of mortality, CMV disease, hepatitis C progression and greater fibrosis scores. Although HHV-6 infection is currently diagnosed by quantifying viral DNA in plasma or blood, biopsy to demonstrate histopathologic effects of HHV-6 remains the gold standard for diagnosis of end-organ disease. HHV-6 reactivation may be restricted to the infected organ with no evidence of active infection in the blood. HHV-6 infections in liver transplant patients are mostly asymptomatic, but clinically significant tissue-invasive infections have been treated successfully with ganciclovir, foscarnet, or cidofovir. Inherited chromosomally-integrated HHV-6 (ciHHV-6), in either the recipient or the donor organ, may create confusion about systemic HHV-6 infection. Recipients with inherited ciHHV-6 may have an increased risk of opportunistic infection and graft rejection. This article reviews the current scientific data on the clinical effects, risk factors, pathogenesis, diagnosis, and treatment of HHV-6 infections in liver transplant recipients. This article is protected by copyright. All rights reserved.

PMID: 28650593 [PubMed - as supplied by publisher]